With a market cap of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems ...

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Insulet today announced that it's bringing its automated insulin delivery technology to a range of new geographies.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its revolutionary Omnipod 5 ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Insulet Corporation’s RADIANT study shows glycaemic improvements with Omnipod 5 automated insulin delivery system: Action, Massachusetts Friday, March 21, 2025, 18:00 Hrs [IST] ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Omnipod 5 is now commercially available in Australia ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...